INmune Bio Inc. Common stock (INMB) Stock Price

INMBStock

$1.57−15.14%52W

Market Cap$43.57M

P/E—

PEG Ratio—

Div yield—

Beta0.93

INMB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.70%

Price vs S&P 500 (4W)-30.12%

VGM Score53.69

Book Value / Share (Quarterly)$0.74

P/TBV (Annual)1.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-48.68%

Cash Flow / Share (Quarterly)$-0.57

Price vs S&P 500 (YTD)-11.29%

Net Profit Margin (TTM)-19478.00%

EPS (TTM)$-0.69

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-0.69

Revenue Growth (5Y)37.97%

EPS (Annual)$-1.86

ROI (Annual)-195.26%

Net Profit Margin (5Y Avg)-87209.13%

Cash / Share (Quarterly)$0.67

ROA (Last FY)-141.98%

Revenue Growth TTM (YoY)257.14%

EBITD / Share (TTM)$-0.75

ROE (5Y Avg)-97.66%

Operating Margin (TTM)-19810.00%

Cash Flow / Share (Annual)$-0.89

P/B Ratio2.14x

P/B Ratio (Quarterly)2.13x

Net Income / Employee (Annual)$-2,187,300

EV / Revenue (TTM)503.25x

Net Interest Coverage (TTM)-52.34x

ROA (TTM)-62.23%

EPS Incl Extra (Annual)$-1.86

Current Ratio (Annual)3.55x

Quick Ratio (Quarterly)3.94x

3-Month Avg Trading Volume0.61M

52-Week Price Return-15.14%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)871.47x

Asset Turnover (Annual)0.00x

52-Week High$2.60

Operating Margin (5Y Avg)-88339.48%

EPS Excl Extra (Annual)$-1.86

Tangible BV CAGR (5Y)1.12%

26-Week Price Return24.60%

Quick Ratio (Annual)3.48x

13-Week Price Return-17.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.04x

Enterprise Value$25.16M

Revenue / Share Growth (5Y)20.11%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-21.00%

Revenue / Employee (Annual)$2,400

Pretax Margin (Annual)-91866.00%

Cash / Share (Annual)$0.93

3-Month Return Std Dev68.23%

Net Income / Employee (TTM)$-877,000

ROE (Last FY)-195.26%

Net Interest Coverage (Annual)-52.22x

EPS Basic Excl Extra (Annual)$-1.86

Receivables Turnover (TTM)0.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.69

Receivables Turnover (Annual)0.05x

ROI (TTM)-82.87%

P/S Ratio (TTM)871.47x

Pretax Margin (5Y Avg)-87209.13%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.88

Price vs S&P 500 (52W)-30.67%

Year-to-Date Return0.64%

5-Day Price Return-11.80%

EPS Normalized (Annual)$-1.86

ROA (5Y Avg)-72.94%

Net Profit Margin (Annual)-91866.00%

Month-to-Date Return-19.49%

EBITD / Share (Annual)$-1.91

Operating Margin (Annual)-94766.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.47%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.69

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)-19478.00%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)-20.05%

Beta0.93x

Revenue / Share (TTM)$0.00

ROE (TTM)-82.87%

52-Week Low$1.09

vGradeD

gGradeA

mGradeC

vgmGradeC

INMB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.20	-$0.05	+75.00%(+$0.15)
Q1 2026	May 7, 2026	-$0.18	-$0.20	-11.11%(-$0.02)
Q4 2025	Mar 30, 2026	-$0.27	-$0.18	+33.33%(+$0.09)
Q3 2025	Oct 30, 2025	-$0.33	-$0.24	+26.15%(+$0.09)
Q2 2025	Aug 7, 2025	-$0.38	-$0.34	+10.27%(+$0.04)

INMB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.10

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
INMBINmune Bio Inc. Common stock	D	A	C	871.5x	257.1%	—	—	$1.57
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About INmune Bio Inc. Common stock

INmune Bio is a clinical-stage biotechnology company developing immunotherapies designed to reprogram patients' innate immune systems to combat cancer. The company's pipeline includes multiple candidates across oncology and other therapeutic areas, positioned to address significant unmet medical needs in immuno-oncology.